Aliases & Classifications for Diabetic Foot Ulcers

MalaCards integrated aliases for Diabetic Foot Ulcers:

Name: Diabetic Foot Ulcers 38 55
Diabetic Foot Ulcer 73
Diabetic Foot 73

External Ids:

Summaries for Diabetic Foot Ulcers

MalaCards based summary : Diabetic Foot Ulcers, also known as diabetic foot ulcer, is related to arteries, anomalies of and vascular disease, and has symptoms including angina pectoris, back pain and chest pain. An important gene associated with Diabetic Foot Ulcers is PDGFB (Platelet Derived Growth Factor Subunit B), and among its related pathways/superpathways are Apoptotic Pathways in Synovial Fibroblasts and GPCR Pathway. The drugs Amoxicillin and Aztreonam have been mentioned in the context of this disorder. Affiliated tissues include Bone, skin and bone, and related phenotypes are cardiovascular system and growth/size/body region

Wikipedia : 76 Diabetic foot ulcer is a major complication of diabetes mellitus, and probably the major component of... more...

Related Diseases for Diabetic Foot Ulcers

Diseases related to Diabetic Foot Ulcers via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 124)
# Related Disease Score Top Affiliating Genes
1 arteries, anomalies of 29.7 APOE IL6 MMP9
2 vascular disease 29.4 APOE IL6 MMP9
3 hypertrophic scars 29.3 TGFB1 TIMP1
4 acute transverse myelitis 10.3 IL6 MMP9
5 photokeratitis 10.3 IL6 MMP9
6 transverse myelitis 10.3 IL6 MMP9
7 rosacea 10.3 IL6 MMP9
8 arteriovenous malformation 10.3 IL6 MMP9
9 ischemic heart disease 10.2 APOE IL6
10 tropical spastic paraparesis 10.2 IL6 MMP9
11 traumatic brain injury 10.2 APOE IL6
12 chorioamnionitis 10.2 IL6 MMP9
13 carotid stenosis 10.2 APOE MMP9
14 intervertebral disc disease 10.2 IL6 MMP9
15 ischemia 10.2
16 tuberculous meningitis 10.2 MMP9 TGFB1
17 brain injury 10.2 APOE IL6
18 bacterial meningitis 10.2 IL6 MMP9
19 gingivitis 10.2 IL6 MMP9
20 brain edema 10.2 IL6 MMP9
21 osteomyelitis 10.2
22 coronary stenosis 10.2 APOE IL6
23 laryngitis 10.1 IL6 TGFB1
24 posterior urethral valves 10.1 IL6 TGFB1
25 communicating hydrocephalus 10.1 APOE TGFB1
26 takayasu arteritis 10.1 IL6 MMP9
27 depression 10.1
28 localized scleroderma 10.1 IL6 TGFB1
29 peripheral artery disease 10.1
30 limb ischemia 10.1
31 bone cancer 10.1 IL6 MMP9
32 idiopathic neutropenia 10.1 IL6 TGFB1
33 rheumatic heart disease 10.1 IL6 TGFB1
34 prostatitis 10.1 IL6 TGFB1
35 critical limb ischemia 10.0
36 diabetes mellitus 10.0
37 endotheliitis 10.0
38 carpal tunnel syndrome 10.0 IL6 TGFB1
39 autoimmune inner ear disease 10.0 MMP9 TIMP1
40 chronic venous leg ulcers 10.0 MMP9 TIMP1
41 pneumoconiosis 10.0 IL6 TGFB1
42 cryptogenic organizing pneumonia 10.0 MMP9 TIMP1
43 conjunctival nevus 10.0 MMP9 TIMP1
44 microcystic meningioma 10.0 MMP9 TIMP1
45 neuropathy 10.0
46 nasal cavity squamous cell carcinoma 10.0 MMP9 TIMP1
47 sleep apnea 10.0 APOE IL6
48 sorsby fundus dystrophy 10.0 MMP9 TIMP1
49 lung giant cell carcinoma 10.0 MMP9 TIMP1
50 cerebral palsy 9.9 APOE IL6

Graphical network of the top 20 diseases related to Diabetic Foot Ulcers:



Diseases related to Diabetic Foot Ulcers

Symptoms & Phenotypes for Diabetic Foot Ulcers

UMLS symptoms related to Diabetic Foot Ulcers:


angina pectoris, back pain, chest pain, edema, headache, muscle cramp, pain, sciatica, seizures, syncope, tremor, chronic pain, vertigo/dizziness, sleeplessness

MGI Mouse Phenotypes related to Diabetic Foot Ulcers:

46 (show all 16)
# Description MGI Source Accession Score Top Affiliating Genes
1 cardiovascular system MP:0005385 10.03 TIMP1 TGFB1 PDGFB APOE MMP9 IL6
2 growth/size/body region MP:0005378 10.01 TGFB1 TIMP1 IL6 PDGFB APOE MMP9
3 hematopoietic system MP:0005397 10 TIMP1 TGFB1 IL6 PDGFB APOE MMP9
4 homeostasis/metabolism MP:0005376 9.99 TGFB1 TIMP1 PDGFB IL6 APOE MMP9
5 immune system MP:0005387 9.97 TIMP1 TGFB1 IL6 PDGFB APOE MMP9
6 mortality/aging MP:0010768 9.91 TGFB1 TIMP1 PDGFB IL6 APOE MMP9
7 integument MP:0010771 9.88 TGFB1 IL6 PDGFB APOE MMP9
8 digestive/alimentary MP:0005381 9.85 TGFB1 IL6 APOE MMP9
9 muscle MP:0005369 9.8 TGFB1 PDGFB APOE MMP9 IL6
10 liver/biliary system MP:0005370 9.76 TGFB1 PDGFB IL6 APOE
11 reproductive system MP:0005389 9.73 TIMP1 TGFB1 APOE MMP9 IL6 PDGFB
12 renal/urinary system MP:0005367 9.72 TGFB1 PDGFB APOE MMP9 IL6
13 neoplasm MP:0002006 9.67 TGFB1 TIMP1 IL6 MMP9
14 respiratory system MP:0005388 9.63 TIMP1 TGFB1 APOE MMP9 IL6 PDGFB
15 skeleton MP:0005390 9.35 TGFB1 TIMP1 IL6 APOE MMP9
16 vision/eye MP:0005391 9.02 TGFB1 IL6 PDGFB APOE MMP9

Drugs & Therapeutics for Diabetic Foot Ulcers

Drugs for Diabetic Foot Ulcers (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 295)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Amoxicillin Approved, Vet_approved Phase 4,Phase 3,Not Applicable 26787-78-0 33613
2
Aztreonam Approved Phase 4,Phase 2 78110-38-0 5362041 5742832
3
Clindamycin Approved, Vet_approved Phase 4,Phase 2 18323-44-9 29029
4
Levofloxacin Approved, Investigational Phase 4,Phase 3,Phase 2 100986-85-4 149096
5
Linezolid Approved, Investigational Phase 4,Phase 2 165800-03-3 441401
6
Metronidazole Approved Phase 4,Phase 2 443-48-1 4173
7
Ofloxacin Approved Phase 4,Phase 3,Phase 2 82419-36-1 4583
8
Piperacillin Approved Phase 4,Phase 3,Phase 2 66258-76-2 43672
9
Tazobactam Approved Phase 4,Phase 3,Phase 2 89786-04-9 123630
10
Ciprofloxacin Approved, Investigational Phase 4,Phase 1,Phase 2,Not Applicable 85721-33-1 2764
11
Sulfamethoxazole Approved Phase 4,Phase 2,Not Applicable 723-46-6 5329
12
Trimethoprim Approved, Vet_approved Phase 4,Phase 2,Not Applicable 738-70-5 5578
13
Zinc Approved, Investigational Phase 4,Phase 3,Not Applicable 7440-66-6 23994
14
Daptomycin Approved, Investigational Phase 4,Phase 3,Phase 2 103060-53-3 16129629
15
Alginic acid Approved, Investigational Phase 4,Phase 1,Phase 2,Not Applicable 9005-32-7
16
Petrolatum Approved, Investigational Phase 4 8009-03-8
17
Cefepime Approved, Investigational Phase 4,Phase 2 88040-23-7 5479537
18
Cefotaxime Approved Phase 4 63527-52-6 456256 5742673
19
Cefoxitin Approved Phase 4 35607-66-0 441199
20
Ceftriaxone Approved Phase 4 73384-59-5 5479530 5361919
21
Doxycycline Approved, Investigational, Vet_approved Phase 4,Phase 2,Phase 1 564-25-0 54671203
22
Fusidic Acid Approved, Investigational Phase 4 6990-06-3 3000226
23
Rifampicin Approved Phase 4 13292-46-1 5458213 5381226
24
Chlorhexidine Approved, Vet_approved Phase 4,Not Applicable 55-56-1 9552079 2713
25
Ampicillin Approved, Vet_approved Phase 4 69-53-4 6249
26
Sulbactam Approved Phase 4 68373-14-8
27 Sultamicillin Approved, Investigational Phase 4 76497-13-7
28
Ertapenem Approved, Investigational Phase 4,Phase 3 153832-46-3 150610
29
Insulin Glargine Approved Phase 4 160337-95-1
30
Linagliptin Approved Phase 4 668270-12-0 10096344
31
Metformin Approved Phase 4,Phase 2 657-24-9 14219 4091
32
Vancomycin Approved Phase 4,Phase 3,Phase 2 1404-90-6 441141 14969
33
Saxagliptin Approved Phase 4 361442-04-8 11243969
34
Dimenhydrinate Approved Phase 4 523-87-5 441281
35
Bacitracin Approved, Vet_approved Phase 4 1405-87-4 439542 10909430
36
Thrombin Approved, Investigational Phase 4,Not Applicable
37
Folic Acid Approved, Nutraceutical, Vet_approved Phase 4,Phase 3,Phase 2,Not Applicable 59-30-3 6037
38
leucovorin Approved, Nutraceutical Phase 4,Phase 2,Not Applicable 58-05-9 143 6006
39
Vitamin C Approved, Nutraceutical Phase 4 50-81-7 5785 54670067
40 Anti-Bacterial Agents Phase 4,Phase 3,Phase 1,Phase 2,Not Applicable
41 Antibiotics, Antitubercular Phase 4,Phase 3,Phase 1,Phase 2,Not Applicable
42 Anti-Infective Agents Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable
43 Antitubercular Agents Phase 4,Phase 3,Phase 2,Not Applicable
44 Clavulanic Acid Phase 4,Phase 3,Phase 2,Not Applicable
45 Clindamycin palmitate Phase 4,Phase 2
46 Clindamycin phosphate Phase 4,Phase 2
47 Gentamicins Phase 4,Phase 3,Phase 2,Phase 1
48 Coagulants Phase 4,Phase 3,Phase 1,Not Applicable
49 Hemostatics Phase 4,Phase 3,Phase 1,Not Applicable
50 Mitogens Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable

Interventional clinical trials:

(show top 50) (show all 544)
# Name Status NCT ID Phase Drugs
1 A Comparative Efficacy Study of DermaPure™ to Treat Diabetic Foot Ulcers Unknown status NCT02081352 Phase 4
2 Maggot Debridement Therapy Versus Conventional Dressing Therapy to Treat Diabetic Foot Ulcers Unknown status NCT02816749 Phase 4
3 Efficacy and Safety of Garamycin® Sponge (Gentamicin-Collagen Sponge) in Diabetic Patients With a Moderate or Severe Foot Ulcer Infection Unknown status NCT01951768 Phase 4 Garamycin Sponge (Gentamicin-Collagen sponge);Systemic Antibiotic
4 Outcomes of Non-infected Diabetic Foot Ulcers With/Without Antibiotics Unknown status NCT01418456 Phase 4 antibiotics
5 Clinical Evaluation of the SNaP Wound Care System Unknown status NCT01113658 Phase 4
6 Santyl Applications to Diabetic Foot Ulcers Completed NCT02111291 Phase 4
7 Grafix® DFU: Open-Label Extension Option to Evaluate Safety & Efficacy of Grafix® for Chronic Diabetic Foot Ulcers Completed NCT01596920 Phase 4
8 LeucoPatch™ Study A Multicenter Study on the Effect of LeucoPatch™ in Diabetic Foot Ulcers Completed NCT01454401 Phase 4
9 Study of Oasis Ultra in Diabetic Foot Ulcers Completed NCT01835379 Phase 4
10 Diabetic Foot Ulcer Study on Topical Interventions Completed NCT02577900 Phase 4
11 Using Santyl on Diabetic Foot Ulcers Completed NCT01408277 Phase 4
12 Use of Santyl in Diabetic Foot Ulcers Completed NCT02581488 Phase 4
13 LeucoPatch in the Management of Hard-to-heal Diabetic Foot Ulcers Completed NCT02224742 Phase 4
14 Evaluation of the Effect of Vivostat Platelet Rich Fibrin(PRF) in the Treatment of Diabetic Foot Ulcers Completed NCT00770939 Phase 4
15 TITLE: An Open, Non-comparative, Multi-centre Post Marketing Clinical Follow-up (PMCF) Investigation to Evaluate Performance and Safety on Diabetic Foot Ulcer, DFU, When Using Mepilex Transfer Ag as Intended Completed NCT01964521 Phase 4
16 A Study to Look at the Effects of Four Weeks of Treatment on the Healing of Diabetic Foot Ulcers Completed NCT01143714 Phase 4 Santyl
17 Enzymatic Versus (vs) Autolytic Debridement of Diabetic Foot Ulcers Completed NCT01143727 Phase 4 Santyl;Tegaderm Hydrogel
18 GrafixCORE®: Open-Label Study to Evaluate the Safety and Efficacy of GrafixCORE® for Complex Diabetic Foot Wounds Completed NCT02260609 Phase 4
19 Santyl vs. Sharp Debridement of Diabetic Foot Wounds Completed NCT01056198 Phase 4 Santyl
20 Antibiotic Treatment Duration for Non-Surgically-Treated Diabetic Foot Osteomyelitis Completed NCT02123628 Phase 4 duration of the antibiotic therapy
21 Trial of Vacuum Assisted Closure® Therapy in Amputation Wounds of the Diabetic Foot Completed NCT00224796 Phase 4
22 Diabetic Foot Ulcer. Effectiveness of Chlorhexidine Gluconate 0.125 % Compared With Sterile Deionized Water Completed NCT02097615 Phase 4
23 Evaluation of the Clinical Effectiveness of a Collagen-ORC Antimicrobial Matrix in Full-Thickness, Neuropathic Diabetic Foot Ulcers Completed NCT00235196 Phase 4
24 GrafixPRIME® for the Treatment of Chronic Diabetic Foot Ulcers Completed NCT02675855 Phase 4
25 OASIS Wound Matrix (Oasis) Mechanism of Action Completed NCT00570141 Phase 4
26 Wound Edge Changes Following Treatment With Santyl Completed NCT01197898 Phase 4
27 Polydeoxyribonucleotide -Placentex Mastelli(Pdrn) for the Treatment of Diabetic Ulcers Completed NCT00638872 Phase 4 Polydeoxyribonucleotide
28 Study Evaluating the Safety and Efficacy of Piperacillin/Tazobactam and Ampicillin/Sulbactam in Patients With Diabetic Foot Infections Completed NCT00044746 Phase 4 Piperacillin/Tazobactam
29 Hyperbaric Oxygen Therapy as Adjunctive Treatment of Chronic Diabetic Foot Ulcers Completed NCT00953186 Phase 4
30 Study Comparing VERSAJET With Conventional Surgical Procedures in the Removal of Unhealthy Tissue From Lower Limb Ulcers Completed NCT00521027 Phase 4
31 Skin Ulcers Treatment With an Handicraft Topical Device Completed NCT02512159 Phase 4
32 Target Site Pharmacokinetics of Ertapenem After Multiple Doses in Diabetes Patients With Soft Tissue Infection Completed NCT00658866 Phase 4
33 Hyperbaric Oxygen Therapy (HBOT) for Chronic Diabetic Lower Limb Ulcers Completed NCT00621608 Phase 4
34 ADA Linagliptin in Long Term Care Completed NCT02061969 Phase 4 linagliptin;insulin glargine
35 Evaluation of Woulgan in Diabetic Foot Ulcer Recruiting NCT02631512 Phase 4
36 A Feasibility Study of the ReGenerCell™ Autologous Cell Harvesting Device for Diabetic Foot Ulcers Recruiting NCT02799121 Phase 4
37 Chlorhexidine Gluconate Solution at 0.125% vs Placebo for the Healing of Grade IIB Ulcers of Diabetic Foot Recruiting NCT03209466 Phase 4 Chlorhexidine gluconate at 0.125%;Placebo Comparator with physiological saline sterile solution
38 Dipeptidyl Peptidase 4 Inhibition Facilitate Healing of Diabetic Ulcers Recruiting NCT02742233 Phase 4 saxagliptin;placebo
39 A Comparison of TCC-EZ Using Human Amnion Allograft vs TCC-EZ and Standard Wound Care in Treating Diabetic Foot Ulcers. Active, not recruiting NCT02344329 Phase 4
40 TruSkin®: Study for the Treatment of Chronic Diabetic Foot Ulcers Terminated NCT02936115 Phase 4
41 A Comparative Efficacy Study: Treatment for Non-healing Diabetic Foot Ulcers Terminated NCT01858545 Phase 4
42 Outpatient Treatment of Gram Positive Wound Infections in the Diabetic Foot: A Pharmaco-economic Comparison of Daptomycin vs. Vancomycin Based Regimens Terminated NCT01133600 Phase 4 Cubicin;Vancomycin
43 Januvia (Sitagliptin) in Healing Chronic Diabetic Foot Ulcers Terminated NCT02015910 Phase 4 Sitagliptin;Placebo
44 Use of INTEGRA™ Flowable Wound Matrix to Manage Diabetic Foot Ulcers Terminated NCT01108263 Phase 4 INTEGRA™ Flowable Matrix (Collagen)
45 RESPOND Restoring Equilibrium and Wound Stimulation to Promote Healing Of Non-healing DFUs Terminated NCT01608776 Phase 4
46 Safety and Efficacy of Daptomycin for the Treatment of Complicated Skin and Skin-structure Infections Terminated NCT00463801 Phase 4 Daptomycin
47 The Relationship of Hemoglobin A1c and Diabetic Wound Healing Terminated NCT01350102 Phase 4 Bacitracin;AmeriGel®
48 a Randomized Controlled Trial Comparing Medical and Medical-surgical Treatment in Diabetic Foot Osteomyelitis Withdrawn NCT00578890 Phase 4
49 A Randomized, Controlled Trial of Autologous Platelet Gel Treatment in Diabetic Foot Ulcers Withdrawn NCT00338702 Phase 4
50 A Prospective, Randomized, Controlled, Multi-Center, Study Evaluating AutoloGel Therapy for Complete Closure of Wagner Grade 1-4 Diabetic Foot Ulcers, Venous Leg Ulcers and Stage II-IV Pressure Ulcers Withdrawn NCT02248077 Phase 4

Search NIH Clinical Center for Diabetic Foot Ulcers

Cell-based therapeutics:


LifeMap Discovery
Data from LifeMap, the Embryonic Development and Stem Cells Database
Read about Diabetic Foot Ulcers cell therapies at LifeMap Discovery.

Genetic Tests for Diabetic Foot Ulcers

Anatomical Context for Diabetic Foot Ulcers

MalaCards organs/tissues related to Diabetic Foot Ulcers:

41
Skin, Bone, Bone Marrow, Endothelial, Testes, Kidney, Colon
LifeMap Discovery
Data from LifeMap, the Embryonic Development and Stem Cells Database

Cells/anatomical compartments in embryo or adult related to Diabetic Foot Ulcers:
# Tissue Anatomical CompartmentCell Relevance
1 Bone Bone Marrow Bone Marrow Stromal Cells Potential therapeutic candidate

Publications for Diabetic Foot Ulcers

Articles related to Diabetic Foot Ulcers:

(show top 50) (show all 702)
# Title Authors Year
1
Dysfunctional Wound Healing in Diabetic Foot Ulcers: New Crossroads. ( 29362914 )
2018
2
Polymicrobial interactions influence the agr copy number in Staphylococcus aureus isolates from diabetic foot ulcers. ( 29796774 )
2018
3
Cost-effectiveness analysis of the human recombinant epidermal growth factor in the management of patients with diabetic foot ulcers. ( 29963295 )
2018
4
Use of Oxidized Regenerated Cellulose/Collagen Matrix in Chronic Diabetic Foot Ulcers: A Systematic Review. ( 29346146 )
2018
5
Growth factors for diabetic foot ulcers: mixed treatment comparison analysis of randomized clinical trials. ( 29148070 )
2018
6
Chinese medicine ulcer oil promotes the healing of diabetic foot ulcers. ( 29916286 )
2018
7
Topical 5% potassium permanganate solution accelerates the healing process in chronic diabetic foot ulcers. ( 29435274 )
2018
8
Topical epidermal growth factor spray for the treatment of chronic diabetic foot ulcers: A phase III multicenter, double-blind, randomized, placebo-controlled trial. ( 29902542 )
2018
9
Perception of diabetic foot ulcers among general practitioners in four European countries: knowledge, skills and urgency. ( 29738299 )
2018
10
Financial burden of diabetic foot ulcers to world: a progressive topic to discuss always. ( 29344337 )
2018
11
Short-term predictors of amputation in patients with diabetic foot ulcers. ( 29802073 )
2018
12
Association between QTc interval prolongation and outcomes of diabetic foot ulcers: Data from a 4-year follow-up study in China. ( 29382590 )
2018
13
Ultrasound-assisted debridement of neuroischaemic diabetic foot ulcers, clinical and microbiological effects: a case series. ( 29738301 )
2018
14
Update on management of diabetic foot ulcers. ( 29377202 )
2018
15
Severe Vitamin D3 Deficiency in the Majority of Patients with Diabetic Foot Ulcers. ( 29975973 )
2018
16
Infected Diabetic Foot Ulcers: No Laterality? ( 29890553 )
2018
17
Osteopontin levels in plasma, muscles, and bone in patient with non-healing diabetic foot ulcers: A new player in wound healing process? ( 29871782 )
2018
18
Critical Appraisal of the Quality of Evidence Addressing the Diagnosis, Prognosis, and Management of Peripheral Artery Disease in Patients With Diabetic Foot Ulceration. ( 29909087 )
2018
19
Incidence of diabetic foot ulcer in Japanese patients with type 2 diabetes mellitus: The Fukuoka diabetes registry. ( 29382584 )
2018
20
Improvement of the Quality of Evidence of Peripheral Artery Disease in Diabetic Foot Ulceration: Small Step for a Doctor, Giant Leap for Mankind? ( 29898825 )
2018
21
Nanosphere-mediated co-delivery of VEGF-A and PDGF-B genes for accelerating diabetic foot ulcers healing in rats. ( 29955127 )
2018
22
Effect of negative pressure wound therapy on molecular markers in diabetic foot ulcers. ( 29758297 )
2018
23
Increasing SBP variability is associated with an increased risk of developing incident diabetic foot ulcers. ( 29794815 )
2018
24
CODIFI (Concordance in Diabetic Foot Ulcer Infection): a cross-sectional study of wound swab versus tissue sampling in infected diabetic foot ulcers in England. ( 29391370 )
2018
25
Role of anaerobes in polymicrobial communities and biofilms complicating diabetic foot ulcers. ( 29863794 )
2018
26
Growth factors in the pathogenesis of diabetic foot ulcers. ( 28930549 )
2018
27
Electromagnetic simulation of non-invasive approach for the diagnosis of diabetic foot ulcers. ( 29881185 )
2018
28
Characterization of the Cicatrization Process in Diabetic Foot Ulcers Based on the Production of Reactive Oxygen Species. ( 29951552 )
2018
29
Intervention planning for the REDUCE maintenance intervention: a digital intervention to reduce reulceration risk among patients with a history of diabetic foot ulcers. ( 29779008 )
2018
30
Specific PKC I^ II Inhibitor: One Stone Two Birds in the Treatment of Diabetic Foot Ulcers. ( 29440456 )
2018
31
Characteristics, prevalence, and outcomes of diabetic foot ulcers in Africa. A systemic review and meta-analysis. ( 29807105 )
2018
32
Presence of chronic diabetic foot ulcers is associated with more frequent and more advanced retinopathy. ( 29791040 )
2018
33
Recurrence of Critical Limb Ischemia After Endovascular Intervention in Patients with Diabetic Foot Ulcers. ( 29892493 )
2018
34
Effect of limb preservation status and body mass index on the survival of patients with limb-threatening diabetic foot ulcers. ( 27751708 )
2017
35
Clinical and surgical characteristics of infected diabetic foot ulcers in a tertiary hospital of Mexico. ( 28904744 )
2017
36
The Impact of Three-month Training Programme on Foot Care and Self-efficacy of Patients with Diabetic Foot Ulcers. ( 28892930 )
2017
37
Differences in the daily activity of patients with diabetic foot ulcers compared to controls in their free-living environments. ( 28707412 )
2017
38
A Retrospective Crossover Study of the Use of Aseptically Processed Placental Membrane in the Treatment of Chronic Diabetic Foot Ulcers. ( 28873060 )
2017
39
The Society for Vascular Surgery Wound, Ischemia, and foot Infection (WIfI) classification system correlates with cost of care for diabetic foot ulcers treated in a multidisciplinary setting. ( 29248237 )
2017
40
Potential of circulatory procalcitonin as a biomarker reflecting inflammation among South Indian diabetic foot ulcers. ( 28736121 )
2017
41
Association of Sociodemographic Factors with Spirituality and Hope in Patients with Diabetic Foot Ulcers. ( 27984272 )
2017
42
NOS1AP genetic variation is associated with impaired healing of diabetic foot ulcers and diminished response to healing of circulating stem/progenitor cells. ( 28755516 )
2017
43
Staphylococcus Aureus Triggers Induction of MIR-15B-5P to Diminish DNA Repair and De-Regulate inflammatory Response in Diabetic Foot Ulcers. ( 29273315 )
2017
44
Cellular versus acellular grafts for diabetic foot ulcers: altering the protocol to improve recruitment to a comparative efficacy trial. ( 29232436 )
2017
45
Recent advances in biomaterials for the treatment of diabetic foot ulcers. ( 28829074 )
2017
46
Sucrose octasulfate dressing versus control dressing in patients with neuroischaemic diabetic foot ulcers (Explorer): an international, multicentre, double-blind, randomised, controlled trial. ( 29275068 )
2017
47
Diabetic Foot Ulcers and Epidermal Growth Factor: Revisiting the Local Delivery Route for a Successful Outcome. ( 28904951 )
2017
48
Management of chronic diabetic foot ulcers using platelet-rich plasma. ( 29244965 )
2017
49
Impact of lysyl oxidase (G473A) polymorphism on diabetic foot ulcers. ( 28522400 )
2017
50
The relationship of Interleukin-6 -174 G>C gene polymorphism in type 2 diabetic patients with and without diabetic foot ulcers in Turkish population. ( 28257947 )
2017

Variations for Diabetic Foot Ulcers

Expression for Diabetic Foot Ulcers

Search GEO for disease gene expression data for Diabetic Foot Ulcers.

Pathways for Diabetic Foot Ulcers

Pathways related to Diabetic Foot Ulcers according to GeneCards Suite gene sharing:

(show all 42)
# Super pathways Score Top Affiliating Genes
1
Show member pathways
13.56 IL6 MMP9 PDGFB TGFB1 TIMP1
2
Show member pathways
13.38 IL6 MMP9 PDGFB TGFB1 TIMP1
3
Show member pathways
13.23 IL6 PDGFB TGFB1 TIMP1
4
Show member pathways
13.13 IL6 PDGFB TGFB1 TIMP1
5
Show member pathways
13.04 IL6 PDGFB TGFB1 TIMP1
6
Show member pathways
13.02 IL6 PDGFB TGFB1 TIMP1
7
Show member pathways
12.98 IL6 PDGFB TGFB1 TIMP1
8
Show member pathways
12.96 IL6 MMP9 PDGFB TGFB1 TIMP1
9
Show member pathways
12.75 IL6 PDGFB TGFB1 TIMP1
10
Show member pathways
12.73 IL6 PDGFB TGFB1 TIMP1
11
Show member pathways
12.52 IL6 MMP9 PDGFB
12 12.52 IL6 MMP9 PDGFB TGFB1
13
Show member pathways
12.39 MMP9 PDGFB TGFB1 TIMP1
14
Show member pathways
12.33 IL6 PDGFB TIMP1
15
Show member pathways
12.32 IL6 PDGFB TGFB1 TIMP1
16 12.17 IL6 PDGFB TGFB1
17
Show member pathways
12.08 IL6 MMP9 PDGFB TGFB1
18 11.92 IL6 MMP9 TGFB1
19 11.81 IL6 PDGFB TGFB1
20 11.73 IL6 MMP9 TGFB1
21
Show member pathways
11.64 IL6 PDGFB TGFB1 TIMP1
22 11.55 IL6 TGFB1
23
Show member pathways
11.5 PDGFB TGFB1
24 11.49 MMP9 TGFB1 TIMP1
25 11.48 MMP9 TGFB1
26 11.48 IL6 MMP9
27
Show member pathways
11.46 IL6 MMP9
28 11.44 MMP9 TIMP1
29 11.35 IL6 TGFB1
30 11.33 IL6 TIMP1
31 11.33 IL6 TGFB1
32 11.31 IL6 MMP9
33 11.31 IL6 MMP9 TGFB1 TIMP1
34 11.27 APOE IL6
35 11.14 IL6 MMP9
36 11.1 APOE MMP9
37 11.07 IL6 TGFB1
38 11.01 IL6 PDGFB TGFB1
39 10.97 MMP9 TIMP1
40 10.95 MMP9 PDGFB
41 10.82 IL6 MMP9 PDGFB TGFB1 TIMP1
42 10.77 MMP9 TGFB1

GO Terms for Diabetic Foot Ulcers

Cellular components related to Diabetic Foot Ulcers according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 extracellular region GO:0005576 9.8 APOE IL6 MMP9 PDGFB TGFB1 TIMP1
2 endoplasmic reticulum lumen GO:0005788 9.46 APOE IL6 PDGFB TIMP1
3 platelet alpha granule lumen GO:0031093 9.43 PDGFB TGFB1 TIMP1
4 extracellular space GO:0005615 9.43 APOE IL6 MMP9 PDGFB TGFB1 TIMP1
5 extracellular matrix GO:0031012 9.02 APOE MMP9 PDGFB TGFB1 TIMP1

Biological processes related to Diabetic Foot Ulcers according to GeneCards Suite gene sharing:

(show all 28)
# Name GO ID Score Top Affiliating Genes
1 positive regulation of gene expression GO:0010628 9.79 IL6 PDGFB TGFB1
2 post-translational protein modification GO:0043687 9.77 APOE IL6 TIMP1
3 positive regulation of apoptotic process GO:0043065 9.76 IL6 MMP9 TGFB1
4 negative regulation of gene expression GO:0010629 9.67 APOE PDGFB TGFB1
5 positive regulation of cell proliferation GO:0008284 9.67 IL6 PDGFB TGFB1 TIMP1
6 cellular protein metabolic process GO:0044267 9.65 APOE IL6 TIMP1
7 extracellular matrix disassembly GO:0022617 9.64 MMP9 TIMP1
8 response to wounding GO:0009611 9.63 PDGFB TGFB1
9 positive regulation of MAP kinase activity GO:0043406 9.63 PDGFB TGFB1
10 positive regulation of cell migration GO:0030335 9.63 MMP9 PDGFB TGFB1
11 positive regulation of smooth muscle cell proliferation GO:0048661 9.62 IL6 PDGFB
12 cellular response to growth factor stimulus GO:0071363 9.61 PDGFB TGFB1
13 positive regulation of fibroblast proliferation GO:0048146 9.61 PDGFB TGFB1
14 positive regulation of blood vessel endothelial cell migration GO:0043536 9.59 PDGFB TGFB1
15 positive regulation of cell division GO:0051781 9.58 PDGFB TGFB1
16 negative regulation of fat cell differentiation GO:0045599 9.57 IL6 TGFB1
17 monocyte chemotaxis GO:0002548 9.56 IL6 PDGFB
18 negative regulation of blood vessel endothelial cell migration GO:0043537 9.55 APOE TGFB1
19 positive regulation of vascular smooth muscle cell proliferation GO:1904707 9.54 MMP9 PDGFB
20 positive regulation of phosphatidylinositol 3-kinase activity GO:0043552 9.52 PDGFB TGFB1
21 positive regulation of pri-miRNA transcription by RNA polymerase II GO:1902895 9.51 PDGFB TGFB1
22 platelet degranulation GO:0002576 9.5 PDGFB TGFB1 TIMP1
23 regulation of signaling receptor activity GO:0010469 9.46 IL6 PDGFB TGFB1 TIMP1
24 cell activation GO:0001775 9.43 TGFB1 TIMP1
25 positive regulation of chemotaxis GO:0050921 9.4 PDGFB TGFB1
26 negative regulation of platelet activation GO:0010544 9.26 APOE PDGFB
27 positive regulation of peptidyl-tyrosine phosphorylation GO:0050731 9.13 IL6 PDGFB TGFB1
28 cytokine-mediated signaling pathway GO:0019221 8.92 IL6 MMP9 TGFB1 TIMP1

Molecular functions related to Diabetic Foot Ulcers according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 identical protein binding GO:0042802 9.46 APOE MMP9 PDGFB TGFB1
2 collagen binding GO:0005518 9.26 MMP9 PDGFB
3 cytokine activity GO:0005125 9.13 IL6 TGFB1 TIMP1
4 growth factor activity GO:0008083 8.92 IL6 PDGFB TGFB1 TIMP1

Sources for Diabetic Foot Ulcers

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
17 ExPASy
19 FMA
28 GO
29 GTR
30 HGMD
31 HMDB
32 HPO
33 ICD10
34 ICD10 via Orphanet
35 ICD9CM
36 IUPHAR
37 KEGG
38 LifeMap
40 LOVD
42 MedGen
44 MeSH
45 MESH via Orphanet
46 MGI
49 NCI
50 NCIt
51 NDF-RT
54 NINDS
55 Novoseek
57 OMIM
58 OMIM via Orphanet
62 PubMed
64 QIAGEN
69 SNOMED-CT via HPO
70 SNOMED-CT via Orphanet
71 TGDB
72 Tocris
73 UMLS
74 UMLS via Orphanet
Content
Loading form....